Integrated Diagnostics Holdings (“IDH,” “the Group,” or “the Company”), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, released today its reviewed financial statements and operational performance for the first half of 2021, recording revenue of EGP 2,293 million, up 141% versus the comparable period of last year. Normalised EBITDA[8] recorded EGP 1,203 million in 1H 2021, representing a 227% year-on-year increase, while net profit expanded 283% year-on-year to reach EGP 668 million for the period. In the second quarter of 2021, revenues reached a new record-high of EGP 1,164 million, up 3% from an already impressive first quarter of the year, with net profit recording EGP 327 million and an associated margin of 28%.
During the six-month period, IDH leveraged a growing branch network, which currently stands at 495 branches, and an expanded house call service to serve 4.7 million patients, 62% above last year’s figure, and conduct 16.3 million tests, up 45% from 1H 2020.
Financial Results
EGP mn 1H 2020 1H 2021 Change
Revenues 950 2,293 141%
Cost of Sales (503) (988) 96%
Gross Profit 446 1,305 193%
Gross Profit Margin 47% 57% 9.9 pts
Operating Profit[9] 277 1,094 291%
Normalised EBITDA2 367 1,203 227%
EBITDA Margin 39% 52% 13.8 pts
Net Profit 175 668 283%
Net Profit Margin 18% 29% 10.8 pts
Cash Balance 719 1,587* 121%
*Cash balance prior to payment of US$ 29.1 million dividend for year ended 31 December 2020, distributed on 29 July 2021.
The Group’s remarkable revenue expansion for the six-month period was driven by both its Covid-19-related tests and a sustained recovery in IDH’s conventional test offering. Although strong and rising demand the Group’s Covid-19-related test offering saw it make up nearly half of its consolidated top-line, the Group’s conventional test offering also recorded robust year-on-year growth of 38% of the period.
Commenting on the Group’s performance for the six-month period, IDH Chief Executive Officer Dr. Hend El-Sherbini said: “Halfway through 2021, I am delighted with the Group’s operational and financial performance, which has seen us continue to build on an impressive start to the year to deliver another set of record-breaking results. Our revenues expanded an impressive 141% versus last year on the back of growing patient and test volumes, improved pricing and an increasingly optimised service mix. While top-line growth continued to be bolstered by our Covid-19-related[10] tests, I am happy to report that we have continued to witness robust growth in our conventional test offering for the second quarter in a row, signalling a sustained recovery which we expect to continue even as Covid-19-related volumes begin to taper off. It is particularly important to highlight that the Group’s conventional test volumes in 1H 2021 surpassed pre-Covid-19 levels, coming in 4% higher than test volumes recorded in the same six months of 2019 after adjusting for the impact of the 100 Million Healthy Lives Campaign[11]. This is further evidence of the robust underlying demand for high quality diagnostic services present across our markets of operation, and of our continued ability to service this growing market.””
Growth in conventional business came on the back of a 29% increase in tests performed versus the comparable period of last year. IDH’s consolidated top-line was also supported by its ramped-up house call service in Egypt and Jordan, which contributed to 23% of consolidated revenue in 1H 2021 compared to 18% in 1H 2020. Through its house call service, IDH served more than 646,000 patients in 1H 2021, up 88% versus 1H 2020, performing more than 3.4 million tests, 49% above the figure recorded in the same period a year ago.
“Our house call services represent an important driver of future growth for the Company well beyond the end of the Covid-19 crisis, and as such we are continuing our efforts to expand and further streamline the service. In parallel, we are also seeing growing contributions coming from our radiology venture, Al-Borg Scan, which recorded year-on-year revenue growth of 124%. To capitalise on the attractive growth opportunities offered by the segment, we are currently aiming to launch at least three new Al-Borg Scan branches over the coming twelve months,” El-Sherbini added.
On a geographic basis, IDH recorded impressive year-on-year growth in both Egypt and Jordan with revenues for 1H 2021 up 140% and 176%, respectively. While demand for Covid-19-related tests in both countries remained high, the Group continued to record robust growth in its conventional test offering, indicating a sustained recovery following last year’s slowdown. In Nigeria, revenue expanded 68% year-on-year supported by growing patient and test volumes. Finally, the Group’s Sudanese operations continued to be impacted by the devaluation of the Sudanese pound earlier in the year. Despite this, the Group was able to deliver a noteworthy 217% year-on-year revenue expansion in local currency terms.
Further down the income statement, IDH reported impressive margin expansions at all levels of profitability supported by strong top-line and the subsequent dilution of IDH’s fixed costs. Gross Profit grew by 193% year-on-year in 1H 2021 to record EGP 1,305 million with an associated margin of 57% versus 47% in the same period last year. Normalised EBITDA[12] reached EGP 1,203 million in 1H 2021, 227% above last year’s figure with a margin of 52%. Finally, net profit expanded nearly fourfold year-on-year to reach a record-high 668 million pounds, with a net profit margin of 29% for the period.
“Heading into the second half of the year, our strategic priorities remain unchanged as we aim to capitalise on the positive momentum witnessed across both our operations and the wider macroeconomic context. In the short-term we will continue to assist governments in Egypt and Jordan in their fight against the Covid-19 pandemic providing our full roster of Covid-19-related services across both our branches and through our expanded house call service. On this front, I am proud of our efforts to secure multiple new partnerships over the last few months to offer PCR testing to travellers in both Egypt and Jordan. This is a key aspect to safeguard the health of passengers and crew members and is further testament to the strong reputation enjoyed by IDH both locally and internationally. Meanwhile, we are working tirelessly to deliver on our post-Covid-19 growth strategy which will see us leverage our expanded patient base, branch network, and service offering to drive new sustainable growth in the years to come. To this end, in the first six months of the year we successfully added 14 new branches in our home market of Egypt, keeping us on track to meet our goal of 30 to 35 new lab rollouts for 2021 and helping us to further cement our leadership position in the country’s private sector diagnostics market. In parallel, we continue to assess potential growth opportunities across new African, Middle Eastern, and Asian markets, and have secured a USD 45 million loan from the International Finance Corporation (IFC) to finance our growth plans in the coming period,” El-Sherbini concluded.
IDH’s full 1H 2021 earnings release for the six-month period ended 30 June 2021 are available at idhcorp.com.